Seres Therapeutics (MCRB) Income towards Parent Company: 2015-2025
Historic Income towards Parent Company for Seres Therapeutics (MCRB) over the last 11 years, with Sep 2025 value amounting to -$21.9 million.
- Seres Therapeutics' Income towards Parent Company fell 115.63% to -$21.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$101.2 million, marking a year-over-year decrease of 184.78%. This contributed to the annual value of $125.9 million for FY2024, which is 64.79% up from last year.
- According to the latest figures from Q3 2025, Seres Therapeutics' Income towards Parent Company is -$21.9 million, which was up 10.17% from -$24.3 million recorded in Q2 2025.
- Over the past 5 years, Seres Therapeutics' Income towards Parent Company peaked at $139.8 million during Q3 2024, and registered a low of -$71.5 million during Q1 2023.
- For the 3-year period, Seres Therapeutics' Income towards Parent Company averaged around -$1.1 million, with its median value being -$7.2 million (2024).
- Data for Seres Therapeutics' Income towards Parent Company shows a peak YoY increase of 2,144.32% (in 2024) and a maximum YoY decrease of 334.82% (in 2024) over the last 5 years.
- Seres Therapeutics' Income towards Parent Company (Quarterly) stood at -$49.7 million in 2021, then spiked by 95.58% to -$2.2 million in 2022, then plummeted by 197.27% to -$6.5 million in 2023, then plummeted by 334.82% to -$28.4 million in 2024, then slumped by 115.63% to -$21.9 million in 2025.
- Its Income towards Parent Company was -$21.9 million in Q3 2025, compared to -$24.3 million in Q2 2025 and -$26.6 million in Q1 2025.